Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL5013319 | 0.96 | — | — | |
| SCHEMBL11198940 | 0.81 | CA2 (0.39) | CA2NFKB1 | |
| SCHEMBL28351730 | 0.75 | CYP3A4 (0.40) | CA2CYP3A4TSHRNFKB1NPSR1 | |
| SCHEMBL587187 | 0.72 | CA2 (0.31) | CA2 | |
| SCHEMBL7186183 | 0.72 | CA2 (0.41) | CA2CYP3A4TSHRNFKB1NPSR1 | |
| SCHEMBL155621 | 0.72 | ALDH1A1 (0.32) | — | |
| SCHEMBL8903392 | 0.71 | CYP3A4 (0.34) | CA2CYP3A4TSHRNFKB1NPSR1 | |
| SCHEMBL587192 | 0.71 | CA1 (0.44) | CA2CYP3A4TSHRNFKB1NPSR1 | |
| SCHEMBL33347 | 0.70 | ALDH1A1 (0.31) | — | |
| SCHEMBL5013321 | 0.70 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472144-B2 | Pharmaceutical composition comprising eliglustat | AMNEAL PHARMACEUTICALS LLC (US) | 2025-11-18 | — | — | US | claimed |
| US-20250332144-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ELIGLUSTAT | AMNEAL PHARMACEUTICALS LLC (US) | 2025-10-30 | — | — | US | claimed |
| US-12440472-B2 | Stable tryptamine oral films | INTELGENX CORP. (CA) | 2025-10-14 | — | — | US | claimed |
| EP-3346998-B1 | TOPICAL FILM DELIVERY SYSTEM | SIDMAK LABORATORIES INDIA PVT LTD (IN) | 2025-04-16 | — | — | EP | claimed |
| US-20250057783-A1 | ORAL FILMS OF ANTIPRURITIC DRUGS | LAURUS LABS LTD (IN) | 2025-02-20 | — | — | US | claimed |
| EP-4456873-A1 | ORAL FILMS OF ANTIPRURITIC DRUGS | Laurus Labs Limited (IN) | 2024-11-06 | — | — | EP | claimed |
| US-12029722-B2 | Dosage delivery film | Spartak LLC (US) | 2024-07-09 | — | — | US | claimed |
| US-20240189299-A1 | ORAL FILM OF CFTR MODULATOR(S) | LAURUS LABS LIMITED (IN) | 2024-06-13 | — | — | US | claimed |
| EP-4304593-A1 | ORAL FILM OF CFTR MODULATOR(S) | Laurus Labs Limited (IN) | 2024-01-17 | — | — | EP | claimed |
| US-20230270716-A1 | GLYCOPYRROLATE ORAL FILM AND IT'S PROCESS | SUVEN PHARMACEUTICALS LIMITED (IN) | 2023-08-31 | — | — | US | claimed |
| WO-1994017132-A9 | ALGAL PLASTICS | — | 1994-09-15 | — | — | WO | claimed |
| WO-1994017132-A1 | ALGAL PLASTICS | INTERNATIONAL TECHNOLOGY MANAGEMENT ASSOCIATES, LTD (US) | 1994-08-04 | — | — | WO | claimed |
| WO-1993020140-A1 | BIODEGRADABLE POLYMER COMPOSITIONS | PARKE-DAVIS & COMPANY (US) | 1993-10-14 | — | — | WO | claimed |
| WO-1993020141-A1 | BIODEGRADABLE STARCH DERIVATIVE COMPOSITIONS | PARKE-DAVIS & COMPANY (US) | 1993-10-14 | — | — | WO | claimed |
| EP-0298920-B1 | DESTRUCTURIZED STARCH CONTAINING A FINITE AMOUNT OF ELECTROLYTES AND PROCESS FOR MAKING SAME | WARNER-LAMBERT COMPANY (US) | 1992-12-09 | — | — | EP | claimed |
| US-4900361-A | Destructurized starch essentially containing no bridged phosphate groups and process for making same | WARNER-LAMBERT COMPANY (US) | 1990-02-13 | — | — | US | claimed |
| EP-0326517-A1 | Method of producing destructurized starch | WARNER-LAMBERT COMPANY (US) | 1989-08-02 | — | — | EP | claimed |
| EP-0304401-A2 | Shaped articles made from pre-processed starch | WARNER-LAMBERT COMPANY (US) | 1989-02-22 | — | — | EP | claimed |
| EP-0298920-A2 | Destructurized starch containing a finite amount of electrolytes and process for making same | WARNER-LAMBERT COMPANY (US) | 1989-01-11 | — | — | EP | claimed |
| US-4268613-A | Agent for protecting the surface of lithographic printing plate | FUJI PHOTO FILM CO., LTD. (JP) | 1981-05-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472144-B2 | Pharmaceutical composition comprising eliglustat | GBA1, GBA2, GALC | CA2 1367/4885CYP3A4 2239/4885TSHR 3783/4885 |
| US-12440472-B2 | Stable tryptamine oral films | TPH1, TPH2, TPSB2 | CA2 2374/4885CYP3A4 320/4885TSHR 2568/4885 |
| US-20230270716-A1 | GLYCOPYRROLATE ORAL FILM AND IT'S PROCESS | PGA5, GYPA, GALR3 | CA2 739/4885CYP3A4 149/4885TSHR 37/4885 |
| US-20250332144-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ELIGLUSTAT | GBA1, GBA2, GALC | CA2 1367/4885CYP3A4 2239/4885TSHR 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.